Vaccinations in juvenile chronic inflammatory diseases: An update

Nature Reviews Rheumatology

Volumn 9, Issue 9, 2013, Pages 532-543

  Silva, Clovis A ^a   Aikawa, Nadia E ^a   Bonfa, Eloisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPHTHERIA VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; PREDNISONE; RUBELLA VACCINE; TETANUS TOXOID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; VARICELLA ZOSTER VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTING CELL; ARTHRALGIA; AUTOINFLAMMATORY DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; CONGESTIVE HEART FAILURE; DENDRITIC CELL; DRUG FEVER; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; JUVENILE DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; JUVENILE SYSTEMIC SCLEROSIS; LYMPHOCYTE DIFFERENTIATION; MALAISE; MEASLES; MUMPS; PRIORITY JOURNAL; RELAPSE; REVIEW; RUBELLA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VARICELLA LIKE RASH; VASCULITIS;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; RHEUMATIC DISEASES; RISK FACTORS; VACCINATION; VACCINES, ATTENUATED;

EID: 84883457622     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.95     Document Type: Review

References (81)

1. Heijstek, M. W. et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann. Rheum. Dis. 70, 1704-1712 (2011).
2. Janow, G. & Ilowite, N. T. Pediatric rheumatic disease: vaccination in pediatric rheumatic disease - risks and benefits. Nat. Rev. Rheumatol. 8, 188-190 (2012).
3. Shoenfeld, Y. & Agmon-Levin, N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36, 4-8 (2011).
4. Dell'Era, L., Esposito, S., Corona, F. & Principi, N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxford) 50, 1358-1365 (2011).
5. Frenck, R. W. & Seward, J. F. Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. (Hoboken) 62, 903-906 (2010).
6. Silva, C. A. et al. Vaccination practice in children with rheumatic disease. Rev. Bras. Reumatol. 50, 351-361 (2010).
7. Davies, K. & Woo, P. British Paediatric Rheumatology Group. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology (Oxford) 41, 937-941 (2002).
8. Morin, M. P., Quach, C., Fortin, E. & Chédeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford) 51, 2046-2050 (2012).
9. McCann, L. J. Should children under treatment for juvenile idiopathic arthritis receive flu vaccination? Arch. Dis. Child. 92, 366-368 (2007).
10. Heijstek, M. W. et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun. Rev. 11, 112-122 (2011).
11. American Academy of Pediatrics. Red Book: 2003 Report of the Committee of Infectious Diseases 26th edn 672-686 (American Academy of Pediatrics, 2003).
12. Cush, J. J.& Kavanaugh, A. Herpes zoster (shingles) vaccine guidelines for immunosuppressed patients. American College of Rheumatology: Hotline [online] http://www.rheumatology.org/ACR/publications/hotline/2008-08- 01-shingles.asp (2008).
13. Aikawa, N. E. et al. Corticosteroid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J. Rheumatol. 39, 167-173 (2012).
14. Aikawa N. et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand. J. Rheumatol. 42, 34-40 (2013).
15. Ogimi, C., Tanaka, R., Saitoh, A. & Oh-Ishi, T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr. Infect. Dis. J. 30, 208-211 (2011).
16. Dell'Era, L. et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 30, 936-940 (2012).
17. Ronaghy, A. et al. Vaccination leads to an aberrant FOXP3 T-cell response in non-remitting juvenile idiopathic arthritis. Ann. Rheum. Dis. 70, 2037-2043 (2011).
18. Miyamoto, M. et al. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus 20, 736-744 (2011).
19. Barbosa, C. M. et al. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin. Exp. Rheumatol. 30, 791-798 (2012).
20. Heijstek, M. W., van Gageldonk, P. G., Berbers, G. A. & Wulffraat, N. M. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann. Rheum. Dis. 71, 948-954 (2012).
21. Toplak, N. et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 30, 436-444 (2012).
22. Miraglia, J. L. et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS ONE 6, 27214 (2011).
23. Shimizu, M., Ueno, K. & Yachie, A. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab. Clin. Vaccine Immunol. 19, 1700-1702 (2012).
24. Shinoki, T. et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod. Rheumatol. 22, 871-876 (2012).
25. Erguven, M., Kaya, B., Hamzah, O. Y. & Tufan, F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile 1. Heijstek, M. W. et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann. Rheum. Dis. 70, 1704-1712 (2011).
26. Erguven, M., Kaya, B., Hamzah, O. Y. & Tufan, F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J. Chin. Med. Assoc. 74, 205-208 (2011).
27. Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747-754 (2011).
28. Campos, L. M. et al. High disease activity: an independent factor for reduced immunogenicity of pandemic influenza a vaccine in patients with juvenile SLE. Arthritis Care Res. (in press).
29. Aytac, M. B. et al. Hepatitis B vaccination in juvenile systemic lupus erythematosus. Clin. Exp. Rheumatol. 29, 882-886 (2011).
30. Long, C. B. et al. Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. J. Pediatr. 160, 74-81 (2012).
31. Guissa, V. R. et al. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. Clin. Exp. Rheumatol. 30, 583-588 (2012).
32. Watanabe, T. Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1). Pediatr. Nephrol. 26, 795-798 (2011).
33. Bodar, E. J. et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 70, 2155-2158 (2011).
34. Bodewes, R., Fraaij, P. L., Osterhaus, A. D. & Rimmelzwaan, G. F. Pediatric influenza vaccination: understanding the T-cell response. Expert Rev. Vaccines 11, 963-971 (2012).
35. Miller, M. A. & Rathore, M. H. Immunization in special populations. Adv. Pediatr. 59, 95-136 (2012).
36. PrabhuDas, M. et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 12, 189-194 (2011).
37. Carneiro-Sampaio, M. & Coutinho, A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv. Immunol. 95, 51-82 (2007).
38. Griffith, L. M. et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J. Allergy Clin. Immunol. 124, 1152-1160 (2009).
39. Linnemann, C. C., Levinson, J. E., Buncher, C. R. & Schiff, G. M. Rubella antibody levels in juvenile rheumatoid arthritis. Ann. Rheum. Dis. 34, 354-358 (1975).
40. Heijstek, M. W. et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann. Rheum. Dis. 66, 1384-1387 (2007).
41. Borte, S., Liebert, U. G., Borte, M. & Sack, U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48, 144-148 (2009).
42. Korematsu, S. et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine 27, 5041-5042 (2009).
43. Kiray, E. et al. Purified protein derivative response in juvenile idiopathic arthritis. J. Rheumatol. 36, 2029-2032 (2009).
44. Pileggi, G. S., de Souza, C. B. & Ferriani, V. P. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. (Hoboken) 62, 1034-1039 (2010).
45. Dhiman, N. et al. Correlations among measles virus-specific antibody, lymphoproliferation and TH1/TH2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin. Exp. Immunol. 142, 498-504 (2005).
46. Malleson, P. N., Tekano, J. L., Scheifele, D. W. & Weber, J. M. Influenza immunization in children with chronic arthritis: a prospective study. J. Rheumatol. 20, 1769-1773 (1993).
47. Olson, N. Y. & Lindsley, C. B. Influenza immunization in children with chronic arthritis. J. Rheumatol. 21, 1581-1582 (1994).
48. Kanakoudi-Tsakalidou, F., Trachana, M., Pratsidou-Gertsi, P., Tsitsami, E. & Kyriazopoulou-Dalaina, V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin. Exp. Rheumatol. 19, 589-594 (2001).
49. Kasapçopur, O. et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann. Rheum. Dis. 63, 1128-1130 (2004).
50. Farmaki, E. et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 28, 5109-5113 (2010).
51. Zonneveld-Huijssoon, E. et al. Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 56, 639-646 (2007).
52. EMA. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application [online], http://archives.who.int/prioritymeds/report/ append/62EMEAguidelines.pdf (2004).
53. EMA. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines [online], http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003945.pdf (1997).
54. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [online], http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf (2007).
55. Kashef, S., Ghazizadeh, F., Derakhshan, A., Farjadian, S. & Alyasin, S. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran. J. Immunol. 5, 181-184 (2008).
56. Ehrengut, W. Dermatomyositis and vaccination. Lancet 1, 1040-1041 (1978).
57. Kåss, E., Straume, S., Mellbye, O. J., Munthe, E. & Solheim, B. G. Dermatomyositis associated with BCG vaccination. Scand. J. Rheumatol. 8, 187-191 (1979).
58. Cotterill, J. A. & Shapiro, H. Dermatomyositis after immunisation. Lancet 2, 1158-1159 (1978).
59. Altman, A., Szyper-Kravitz, M. & Shoenfeld, Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol. Int. 28, 609-612 (2008).
60. Khaled, A. et al. Postvaccination morphea profunda in a child. Pediatr. Dermatol. 29, 525-527 (2012).
61. Benmously Mlika, R. et al. Morphea profunda in a young infant after hepatitis B vaccination. J. Am. Acad. Dermatol. 63, 1111-1112 (2010).
62. Torrelo, A. et al. Deep morphea after vaccination in two young children. Pediatr. Dermatol. 23, 484-7 (2006).
63. Goodman, M. J., Nordin, J. D., Belongia, E. A., Mullooly, J. P. & Baggs, J. Henoch-Schölein purpura and polysaccharide meningococcal vaccine. Pediatrics 126, 325-329 (2010).
64. Watanabe, T. & Onda, H. Henoch-Schönlein purpura with antiphospholipid antibodies following an influenza vaccination. Pediatr. Nephrol. 16, 458-459 (2001).
65. Ozaki, T., Miwata, H., Kodama, H., Matsui, Y. & Asano, Y. Henoch-Schönlein purpura after measles immunization. Acta. Paediatr. Jpn. 31, 484-486 (1989).
66. Lambert, E. M., Liebling, A., Glusac, E. & Antaya, R. J. Henoch-Schönlein purpura following a meningococcal vaccine. Pediatrics 112, e491 (2003).
67. Courtney, P. A., Patterson, R. N. & Lee, R. J. Henoch-Schönlein purpura following meningitis C vaccination. Rheumatology (Oxford) 40, 345-346 (2001).
68. Mormile, R., D'Alterio, V., Treccagnoli, G. & Sorrentino, P. Henoch-Schönlein purpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children? Vaccine 23, 567-568 (2004).
69. Schmöeller, D., Keiserman, M. W., Staub, H. L., Velho, F. P. & de Fátima Grohe, M. Yellow fever vaccination and Kawasaki disease. Pediatr. Infect. Dis. J. 28, 1037-1038 (2009).
70. Miron, D., Fink, D. & Hashkes, P. J. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin. Rheumatol. 22, 461-463 (2003).
71. Sexton, K. et al. Henoch-Schönlein purpura and meningococcal B vaccination. Arch. Dis. Child. 94, 224-226 (2009).
72. Center, K. J., Hansen, J. R., Lewis, E., Fireman, B. H. & Hilton B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 28, 438-440 (2009).
73. Hua, W. et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr. Infect. Dis. J. 28, 943-947 (2009).
74. Chalmers, D., Corban, J. G. & Moore, P. P. BCG site inflammation: a useful diagnostic sign in incomplete Kawasaki disease. J. Paediatr. Child Health 44, 525-526 (2008).
75. Kuniyuki, S. & Asada, M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J. Am. Acad. Dermatol. 37, 303-304 (1997).
76. Weinstein, M. Inflammation at a previous inoculation site: an unusual presentation of Kawasaki disease. CMAJ 174, 459-460 (2006).
77. Antony, D. & Jessy, P. L. Involvement of BCG scar in Kawasaki disease. Indian Pediatr. 42, 83-84 (2005).
78. Hsu, Y. H., Wang, Y. H., Hsu, W. Y. & Lee, Y. P. Kawasaki disease characterized by erythema and induration at the Bacillus Calmette-Guérin and purified protein derivative inoculation sites. Pediatr. Infect. Dis. J. 6, 576-578 (1987).
79. Sinha, R. & Balakumar, T. BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease. Arch. Dis. Child. 90, 891 (2005).
80. Uehara, R., Igarashi, H., Yashiro, M., Nakamura, Y. & Yanagawa, H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. Pediatr. Infect. Dis. J. 29, 430-433 (2010).
81. Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W. & Simon, A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63, 260-264 (2005).